DK1365762T3 - Fremgangsmåde til forögelse af leptinniveauer under anvendelse af nicotinsyreforbindelser - Google Patents

Fremgangsmåde til forögelse af leptinniveauer under anvendelse af nicotinsyreforbindelser

Info

Publication number
DK1365762T3
DK1365762T3 DK02721337T DK02721337T DK1365762T3 DK 1365762 T3 DK1365762 T3 DK 1365762T3 DK 02721337 T DK02721337 T DK 02721337T DK 02721337 T DK02721337 T DK 02721337T DK 1365762 T3 DK1365762 T3 DK 1365762T3
Authority
DK
Denmark
Prior art keywords
nicotinic acid
leptin levels
acid compounds
increasing leptin
increase
Prior art date
Application number
DK02721337T
Other languages
Danish (da)
English (en)
Inventor
Elaine Jacobson
Myron K Jacobson
Hyuntae Kim
Original Assignee
Univ Kentucky Res Found
Univ Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23047813&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1365762(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Kentucky Res Found, Univ Arizona filed Critical Univ Kentucky Res Found
Application granted granted Critical
Publication of DK1365762T3 publication Critical patent/DK1365762T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK02721337T 2001-03-08 2002-03-08 Fremgangsmåde til forögelse af leptinniveauer under anvendelse af nicotinsyreforbindelser DK1365762T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27434901P 2001-03-08 2001-03-08
PCT/US2002/007256 WO2002072092A1 (en) 2001-03-08 2002-03-08 Method for increasing leptin levels using nicotinic acid compounds

Publications (1)

Publication Number Publication Date
DK1365762T3 true DK1365762T3 (da) 2008-11-17

Family

ID=23047813

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02721337T DK1365762T3 (da) 2001-03-08 2002-03-08 Fremgangsmåde til forögelse af leptinniveauer under anvendelse af nicotinsyreforbindelser

Country Status (12)

Country Link
US (2) US6750234B2 (https=)
EP (1) EP1365762B1 (https=)
JP (1) JP5057353B2 (https=)
CN (1) CN1265792C (https=)
AT (1) ATE409037T1 (https=)
CA (1) CA2437844C (https=)
DE (1) DE60229041D1 (https=)
DK (1) DK1365762T3 (https=)
ES (1) ES2315358T3 (https=)
MX (1) MXPA03008096A (https=)
PT (1) PT1365762E (https=)
WO (1) WO2002072092A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2416788A1 (en) 2000-07-31 2002-02-07 Tamar Tennenbaum Methods and pharmaceutical compositions comprising protein kinase c isoforms for healing wounds
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US6750234B2 (en) * 2001-03-08 2004-06-15 University Of Kentucky Research Foundation Methods for increasing leptin levels using nicotinic acid compounds
BR0315942A (pt) * 2002-11-27 2005-10-04 Dmi Biosciences Inc Tratamento de doenças e condições mediadas pelo aumento de fosforilação
US7736636B2 (en) * 2003-02-12 2010-06-15 Shaker Mousa Method for treating occlusive vascular diseases & wound healing
US9544860B2 (en) 2003-02-24 2017-01-10 Qualcomm Incorporated Pilot signals for use in multi-sector cells
US7218948B2 (en) 2003-02-24 2007-05-15 Qualcomm Incorporated Method of transmitting pilot tones in a multi-sector cell, including null pilot tones, for generating channel quality indicators
US8811348B2 (en) 2003-02-24 2014-08-19 Qualcomm Incorporated Methods and apparatus for generating, communicating, and/or using information relating to self-noise
WO2005013885A2 (en) 2003-08-07 2005-02-17 Healor Ltd. Pharmaceutical compositions and methods for accelerating wound healing
US8969291B2 (en) 2004-10-08 2015-03-03 Enzo Therapeutics, Inc. Methods for decreasing leptin levels or activity for treating inflammation
NZ555079A (en) 2004-10-14 2010-04-30 Qualcomm Inc Methods and apparatus for determining, communicating and using information which can be used for interference control purposes
US8503938B2 (en) 2004-10-14 2013-08-06 Qualcomm Incorporated Methods and apparatus for determining, communicating and using information including loading factors which can be used for interference control purposes
JP2006253769A (ja) * 2005-03-08 2006-09-21 National Institute Of Advanced Industrial & Technology 情報処理システムおよび方法
EP1898867B1 (en) 2005-06-24 2017-08-09 Arizona Board of Regents, acting on behalf of the University of Arizona Method for treating hair growth disorders, such as female pattern alopecia, and compositions useful therefore
EP2452686A3 (en) 2005-08-29 2012-09-05 HealOr Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
US20070066512A1 (en) * 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
US9191840B2 (en) 2005-10-14 2015-11-17 Qualcomm Incorporated Methods and apparatus for determining, communicating and using information which can be used for interference control
US8694042B2 (en) 2005-10-14 2014-04-08 Qualcomm Incorporated Method and apparatus for determining a base station's transmission power budget
US9572179B2 (en) 2005-12-22 2017-02-14 Qualcomm Incorporated Methods and apparatus for communicating transmission backlog information
US9451491B2 (en) 2005-12-22 2016-09-20 Qualcomm Incorporated Methods and apparatus relating to generating and transmitting initial and additional control information report sets in a wireless system
US9148795B2 (en) 2005-12-22 2015-09-29 Qualcomm Incorporated Methods and apparatus for flexible reporting of control information
US9125092B2 (en) 2005-12-22 2015-09-01 Qualcomm Incorporated Methods and apparatus for reporting and/or using control information
US7801589B2 (en) 2005-12-22 2010-09-21 Olympus Corporation In-vivo examination method and in-vivo examination apparatus
US9125093B2 (en) 2005-12-22 2015-09-01 Qualcomm Incorporated Methods and apparatus related to custom control channel reporting formats
US8514771B2 (en) 2005-12-22 2013-08-20 Qualcomm Incorporated Methods and apparatus for communicating and/or using transmission power information
US9137072B2 (en) 2005-12-22 2015-09-15 Qualcomm Incorporated Methods and apparatus for communicating control information
US9338767B2 (en) 2005-12-22 2016-05-10 Qualcomm Incorporated Methods and apparatus of implementing and/or using a dedicated control channel
US8437251B2 (en) 2005-12-22 2013-05-07 Qualcomm Incorporated Methods and apparatus for communicating transmission backlog information
US9473265B2 (en) 2005-12-22 2016-10-18 Qualcomm Incorporated Methods and apparatus for communicating information utilizing a plurality of dictionaries
US9119220B2 (en) 2005-12-22 2015-08-25 Qualcomm Incorporated Methods and apparatus for communicating backlog related information
US20070249360A1 (en) 2005-12-22 2007-10-25 Arnab Das Methods and aparatus related to determining, communicating, and/or using delay information in a wireless communications system
US20070243882A1 (en) 2006-04-12 2007-10-18 Qualcomm Incorporated Method and apparatus for locating a wireless local area network associated with a wireless wide area network
WO2008026349A1 (fr) * 2006-08-31 2008-03-06 Juridical Foundation Osaka Industrial Promotion Organization Agent thérapeutique destiné au traitement de l'effluvium télogène
JP5699414B2 (ja) * 2007-02-28 2015-04-08 ユニバーシティー オブ ケンタッキー リサーチ ファウンデイション レチノイン酸療法の効力を妨げることなくレチノイン酸療法の副作用を軽減する方法、および／又は、その効力を改善する方法
EP2523677A2 (en) 2010-01-11 2012-11-21 Healor Ltd. Method for treatment of inflammatory disease and disorder
CN109414424A (zh) * 2016-04-22 2019-03-01 无锡杰西医药股份有限公司 异硫氰酸酯类化合物的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4505896A (en) * 1979-04-19 1985-03-19 Elorac, Ltd. Method of treating acne vulgaris and composition
DE3110611A1 (de) * 1981-03-18 1982-10-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen "mitogene der leukozyten und des entzuendungsgewebes:natuerliche leukopoetine zur selektiven anregung der teilung und differenzierung von leukozyten"
GB8330969D0 (en) * 1983-11-21 1983-12-29 Wellcome Found Promoting healing
DE3570598D1 (en) * 1984-11-15 1989-07-06 Nitto Denko Corp Composition for percutaneous administration
US4965252A (en) * 1988-06-28 1990-10-23 Hauser-Kuhrts, Inc. Cholesterol-lowering combination compositions of guar gum and niacin
EP0573568B1 (en) * 1991-03-01 2001-01-24 University Of Florida Research Foundation, Inc. Use of nicotinic analogs for treatment of degenerative diseases of the nervous system
US5240945A (en) * 1992-02-18 1993-08-31 Warshaw Thelma G Method and compositions for treating acne
US5612382A (en) * 1994-07-15 1997-03-18 Frances B. Fike Composition for percutaneous absorption of pharmaceutically active ingredients
US5496827A (en) * 1994-07-15 1996-03-05 Patrick; Jay Compositions for the transdermal delivery of nutrients
AU5524896A (en) * 1995-03-20 1996-10-08 Institut Pasteur De Lille Modulators of ob gene and screening methods therefor
DK0823897T3 (da) * 1995-05-01 2004-12-06 Scarista Ltd Nicotinsyreestere og farmaceutiske præparater indeholdende disse
WO1998052927A1 (en) * 1997-05-19 1998-11-26 Rosemarie Scivoletto Composition for treating skin conditions
WO1999059614A1 (en) * 1998-05-20 1999-11-25 Yale University Modulation of angiogenesis and wound healing
PT1143954E (pt) * 1998-12-01 2004-12-31 Univ Kentucky Res Found Utilizacao de derivados de acido nocotinico para o tratamento de danos no adn em celulas da pele
IT1306141B1 (it) * 1999-05-17 2001-05-30 Giampiero Valletta Composizione per il trattamento del prurito uremico e di forme diprurito non riconducibili a lesioni organiche.
US6326034B1 (en) * 1999-12-22 2001-12-04 Natural Compounds Ltd Natural extracted and synthetic antioxidant compositions
US6750234B2 (en) * 2001-03-08 2004-06-15 University Of Kentucky Research Foundation Methods for increasing leptin levels using nicotinic acid compounds

Also Published As

Publication number Publication date
US20040198776A1 (en) 2004-10-07
CN1265792C (zh) 2006-07-26
WO2002072092A1 (en) 2002-09-19
PT1365762E (pt) 2008-11-27
EP1365762A4 (en) 2005-05-25
EP1365762B1 (en) 2008-09-24
CA2437844A1 (en) 2002-09-19
JP5057353B2 (ja) 2012-10-24
ES2315358T3 (es) 2009-04-01
HK1065941A1 (en) 2005-03-11
MXPA03008096A (es) 2005-10-05
JP2004519488A (ja) 2004-07-02
ATE409037T1 (de) 2008-10-15
US6750234B2 (en) 2004-06-15
DE60229041D1 (de) 2008-11-06
CN1496260A (zh) 2004-05-12
CA2437844C (en) 2007-05-15
EP1365762A1 (en) 2003-12-03
US20020128298A1 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
DK1365762T3 (da) Fremgangsmåde til forögelse af leptinniveauer under anvendelse af nicotinsyreforbindelser
WO2001081312A3 (en) Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
BRPI0416909A (pt) método de tratamento de aterosclerose
WO2005016859A3 (en) Proteasome inhibitors and methods of using the same
IS8395A (is) Fjölvasýklískar karboxýlsýrur og asýlsúlfónamíð sem hindrar á lifrabólgu C eftirmyndun
WO2003032914A3 (en) Methods for treating substance abuse with cholinesterase inhibitors
IL217623A (en) Amino-carbonyl-boron compound is converted
SE0301882D0 (sv) New use I
SE0301886D0 (sv) New use V
WO2007112000A3 (en) Treatment of pain
WO2005030120A3 (en) Antiangiogenic agents
TW200503668A (en) Nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors
DK1603577T3 (da) Forbindelser til behandling af smerte
DE60231050D1 (de) Verwendung von Totarol zur Behandlung von Pruritus
IL162384A0 (en) Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
DE60230155D1 (de) Verwendung von verzweigtkettigen fettsäuren und ihrer derivate zur schmerzbehandlung
EP1627635A3 (en) Benzothiazolium compounds for use in methods of inhibiting NO production and TNF alpha and treating coronaviral infection
BG105953A (bg) Метод за лечение на хронична обструктивна белодробна болест
SE0004101D0 (sv) New use
NZ519722A (en) Treatment of diabetic ulcers
TW200600084A (en) Anti-coronavirus compounds
WO2003053352A3 (en) Therapeutic compounds for treating dyslipidemic conditions
DK1353660T3 (da) Anvendelse af substituerede 6-dimethylaminomethyl-1-phenylcyclohexanforbindelser til behandling af urininkontinens